Abstract Details
Activity Number:
|
170
|
Type:
|
Topic Contributed
|
Date/Time:
|
Monday, August 5, 2013 : 10:30 AM to 12:20 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract - #309029 |
Title:
|
Missing Data Imputation Under Intention-to-Treat
|
Author(s):
|
Steven Snapinn*+
|
Companies:
|
Amgen
|
Keywords:
|
Clinical Trials ;
Missing Data ;
Intention-to-treat ;
Imputation
|
Abstract:
|
The statistical and medical literature is nearly unanimous in the recommendation to avoid or prevent missing data whenever possible, which seems to be synonymous with a recommendation to adhere to the intention-to-treat principle. Of course, perfect adherence to intention-to-treat is typically not possible, and nearly every clinical trial has some degree of missing data. There are various alternative approaches for imputing missing data, but it is not clear how compatible these approaches are with intention-to-treat. In this presentation, I'll discuss the concept of missing data imputation for clinical trials intended to be conducted and analyzed under intention-to-treat, and provide recommendations.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.